Edition:
India

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

84.91USD
8:27pm IST
Change (% chg)

$0.20 (+0.24%)
Prev Close
$84.71
Open
$84.93
Day's High
$85.43
Day's Low
$84.61
Volume
278,405
Avg. Vol
1,561,025
52-wk High
$85.43
52-wk Low
$60.32

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.57
Market Cap(Mil.): $95,559.38
Shares Outstanding(Mil.): 1,737.44
Dividend: 0.26
Yield (%): 1.93

Financials

Abbott device helps in cutting blood sugar in type 2 diabetics: study

Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.

11 Jun 2019

CORRECTED-Abbott device helps in cutting blood sugar in type 2 diabetics - study (June 8)

June 8 Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.

11 Jun 2019

UPDATE 2-Abbott Labs quarterly beat overshadowed by unchanged forecast

April 17 Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.

17 Apr 2019

Abbott Labs beats first-quarter expectations on higher diabetes devices sales

Abbott Laboratories Inc reported higher-than-expected first-quarter profit and sales on Wednesday on surging sales of its Freestyle Libre glucose monitoring device and as more of its heart devices were used in surgical procedures.

17 Apr 2019

Abbott Lab's first-quarter sales beat expectations

April 17 Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures.

17 Apr 2019

MEDIA-Abbott shifts to digital health services in India - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

20 Mar 2019

UPDATE 3-Abbott misses revenue estimates, sees lackluster first-qtr profit

Jan 23 Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.

24 Jan 2019

Abbott Labs says M&A not a high priority now

Jan 23 Healthcare company Abbott Laboratories will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.

23 Jan 2019

Abbott Lab's fourth-quarter revenue rises 2.3 pct

Jan 23 Abbott Laboratories posted a 2.3 percent rise in fourth-quarter revenue on Wednesday, helped by growing demand for its heart valves and glucose monitoring devices.

23 Jan 2019

Earnings vs. Estimates